Unknown PHASE2 INTERVENTIONAL 1-arm NCT05290935

Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial

Anti-PD-1 Antibody Camrelizumab Combined With Albumin-bound Paclitaxel for Recurrent and Persistent Advanced Cervical Cancer Refractory to Platinum-based Chemotherapy: A Single Arm, Multi-Center, Open, Phase II Trial

Sponsor: Lei Li

Conditions Albumin-bound Paclitaxel Anti-PD-1 Antibody Chemotherapy Immune Checkpoint Inhibitors Persistent Advanced Cervical Carcinoma Recurrent Cervical Carcinoma

Interventions Albumin-bound paclitaxel Anti-PD-1 antibody camrelizumab

Updated 4 times since 2022 Last updated: Mar 12, 2022 Started: Mar 13, 2022 Primary completion: Dec 13, 2022 Completion: Mar 13, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Albumin-bound Paclitaxel and Anti-PD-1 Antibody and is currently ongoing. Lei Li leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Apr 2024 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Apr 2022 — Apr 2024 [monthly]

Recruiting PHASE2

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lei Li

Data source: Peking Union Medical College Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China